N/A N=16 Surface Stimulation for Female Sexual Dysfunction
Female Sexual Dysfunction
Primary: 6 Weeks - Total FSFI Score — 26.0; 17.4 score on a scale — p=0.109
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=9 Novel Topical Therapies for the Treatment of Genital Pain
Female Genital Diseases
Primary: Reduction in Daily Genital Pain. — 2.4; 2.92; 3.42; 2.77 units on a scale — p=0.30
N/A N=156 Typing of Human Papilloma Virus (HPV) From Female Genital Warts
Genital Warts · Human Papilloma Virus
Primary: HPV DNA and HIV Status — 96; 19; 4; 5 participants
N/A N=705 Women's Improvement of Sexual Health (WISH) Demonstration Project
Sexually Transmitted Disease · Bacterial Vaginosis · Vaginal Candidiasis
Primary: Feasibility of Integrating Point-of-care Testing (Monitoring & Evaluation Indicators) — 396; 378; 399; 216 Participants
N/A N=351 Point of Care Diagnosis of Vaginal Infections
Vaginitis · Bacterial Vaginosis · Yeast Vaginitis
Primary: Number of Participants Prescribed Appropriate Treatment — 61; 104; 58; 21 Participants — p=<.001
N/A N=100 Laser Therapy for Treatment of Urogenital Symptoms in Women
Genitourinary System; Disorder, Female · Burning Vagina · Dyspareunia
Primary: Patient Global Impression of Improvement (PGI-I) Score at 4 Weeks After Initial Treatment — 2.66 score on a scale
Phase 3 N=1,365 Bacterial Vaginosis Home Screening to Prevent STDs
Bacterial Vaginosis
Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…
Phase 3 N=302 The Vaginal Health Trial
Atrophy of Vagina · Menopause · Dyspareunia (Female)
Primary: Most Bothersome Symptom (MBS) Severity — -1.2; -1.0; -0.2; -1.4 units on a scale — p=0.25
Phase 2 N=9 CC-10004 For The Treatment Of Vulvodynia
Vulvodynia
Primary: Global Response Assessment — 5 participants
N/A N=127 The Human Papilloma Virus Effect on Sexual Life
Human Papillomavirus Infection
Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale
Phase 2 N=209 Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments
Vestibulodynia · Temporomandibular Disorder · Fibromyalgia Syndrome
Primary: Pain Score During the Tampon Test — 4.37; 3.75; 4.04; 4.36 score on a scale — p=0.3630
N/A N=328 Diagnostic Accuracy of "Three Rings Vulvoscopy" for Detection of Vulvar Dermatosis
Lichen Sclerosus · Lichen Planus · Lichen Simplex Chronicus
Primary: Diagnostic Accuracy of "Three Rings Vulvoscopy" by the "Vulvoscopy Index" for Detection of Vulvar Dermatosis — 72; 0; 10; 246 Participants — p=0.6108
Phase 4 N=60 Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial
HIV Infection · Vaginal Atrophy · Menopause
Primary: Change in Most Bothersome Symptom (MBS) of Vaginal Atrophy — 0; 1; 8; 4 Participants
Phase 2 N=234 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women
Bacterial Vaginosis · Candidiasis · Trichomoniasis
Primary: Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights…
N/A N=26 Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Clinical Cure Rate at Day 7-14 — 10; 16 Participants
N/A N=88 GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
Genital Herpes
Primary: Time to Healing of Genital Lesions — 5.1; 6.0 Days
Phase 3 N=1,892 Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection
Sexually Transmitted Diseases · Gonorrhea · Chlamydia
Primary: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups — 684; 696 Participants
N/A N=1,585 Clinical Study of a Diagnostic Device for NG, TV and CT in Women
Chlamydial Infection · Gonococcal Infection · Trichomoniasis
Primary: The i) Percent Sensitivity and ii) Percent Specificity of Click Device for Detection of Chlamydia Trachomatis (CT) in Self-collected Vaginal Specimens as Compared to PIS…
Phase 3 N=511 Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
Genital Warts
Primary: Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study. — 0.248; 0.294; 0.09 proportion of participants
N/A N=10 Levels of Raltegravir in the Female Genital Tissue
HIV
Primary: Tissue Raltegravir Concentrations — 117 ng/mL
Phase 3 N=470 Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
Genital Warts
Primary: Proportion of Subjects With Complete Clearance of All Warts (Both Presented at Baseline and Newly Emerged Warts) at End of Study — 0.191; 0.272; 0.103 participants
N/A N=519 A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test
Bacterial Vaginosis · Urogenital Infection by Trichomonas Vaginalis
Primary: Sensitivity of the OSOM Rapid Test and PCR Wet Mount Microscopy in Diagnosing Trichomonas Vaginalis in Symptomatic and Asymptomatic Women — 92; 91; 100; 100 Percentage…
Phase 3 N=289 An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
Psoriasis
Primary: Percentage of Participants With a Modified sPGA-G Response at Week 16 — 19.5; 39.6 Percentage of participants — p=0.0003
Phase 2 N=108 Topical NVN1000 for the Treatment of External Genital and Perianal Warts
Genital Warts · Perianal Warts
Primary: Efficacy: Complete Clearance of Baseline External Genital and Perianal Warts at or Before Week 12 — 2; 5; 2; 10 Participants
N/A N=47 Radiofrequency and Hybrid Fractional Laser for Vaginal Rejuvenation
Vaginal Atrophy
Primary: Vulvovaginal Symptoms Questionnaire — 8; 7.88; 5.93; 5.93 score on a scale
N/A N=24 Clinical Performance of a Vaginal Pessary (pHyph) in Bacterial Vaginosis
Bacterial Vaginosis
Primary: Clinical Cure Rate — 18 Participants
Phase 4 N=25 Preventing Recurrent UTI With Vaginal Estrogen
Recurrent Urinary Tract Infection · Urinary Tract Infections · Cystitis Recurrent
Primary: Change in Vaginal Microbiota — 2.75 change in percent relative abundance
N/A N=23 Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Clinical Cure Rate — 9 Participants
Phase 2 N=30 Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals
HIV-1-infection
Primary: Concentration of Doravirine in Seminal Plasma Fluid — 127 ng/ml
N/A N=48 Women SHARE Study: Reducing Sexual Risk
Alcohol and Substance-Related Mental Disorders · Sexually Transmitted Diseases
Primary: Feasibility of Providing Intervention — 25; 22 Participants